Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - A meta-analysis

International Journal of Cardiology

Volumn 128, Issue 2, 2008, Pages 166-171

  Sofi, Francesco ^a   Marcucci, Rossella ^a   Gori, Anna Maria ^a   Abbate, Rosanna ^a   Gensini, Gian Franco ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Antiplatelet therapy; Aspirin; Meta analysis; Recurrence; Residual platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE;

ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECURRENCE;

EID: 47749143702     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.12.010     Document Type: Review

References (27)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
3. Hovens M.M.C., Snoep J.D., Eikelboom J.C.J., van der Bom J.G., Mertens B.J.A., and Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 153 (2007) 175-181
4. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
5. Helgason C.M., Bolin K.M., Hoff J.A., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
6. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
7. Snoep J.D., Hovens M.M.C., Eikenboom J.C.J., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
8. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
9. Andersen K., Hurlen M., Amesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2003) 37-42
10. Marcucci R., Paniccia R., Antonucci E., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 98 (2006) 1156-1159
11. Gianetti J., Parri M.S., Sbrana S., et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 118 (2006) 487-493
12. Fuchs I., Frossard M., Spiel A., Riedmuller E., Laggner A.N., and Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 4 (2006) 2547-2552
13. Stejskal D., Vaclavik J., Lacnak B., and Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 17 (2006) 349-354
14. Pamukcu B., Oflaz H., Oncul A., et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 22 (2006) 103-110
15. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 (2006) 542-549
16. Malek L.A., Spiewak M., Filipiak K.J., et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 65 (2007) 40-45
17. Pamukcu B., Oflaz H., Onur I., et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul Fibrinolysis 18 (2007) 187-192
18. Poulsen T.S., Kristensen R.S., Korsholm L., et al. Variation and importance of aspirin resistance in patients with cardiovascular disease. Thromb Res 120 (2007) 477-484
19. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 147 (2004) 293-300
20. Valles J., Santos M.T., Aznar J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97 (1998) 350-355
21. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101 (2000) 1013-1018
22. Cipollone F., Rocca B., and Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24 (2004) 246-255
23. Giusti B., Gori A.M., Marcucci R., et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis (2006) doi:10.16/j.atherosclerosis.2006.11.009
24. Mannini L., Marcucci R., Paniccia R., et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin Hemorheol Microcirc 35 (2006) 175-181
25. Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P.P., and Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43 (2004) 979-984
26. Paniccia R., Antonucci E., Gori A.M., et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high risk patients with ischemic heart disease on dual antiplatelet treatment. Am J Clin Pathol 128 (2007) 143-149
27. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311